Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Abstract Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICI...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Adam Lauko, Rupesh Kotecha, Addison Barnett, Hong Li, Vineeth Tatineni, Assad Ali, Pradnya Patil, Alireza M. Mohammadi, Samuel T. Chao, Erin S. Murphy, Lilyana Angelov, John H. Suh, Gene H. Barnett, Nathan A. Pennell, Manmeet S. Ahluwalia
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/e1027f0afb7f466d803752a48a7d5614
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/e1027f0afb7f466d803752a48a7d5614

Documents similaires